Page 1 | Search Results | Blood Advances | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America

Ignacio Neumann, Ariel Izcovich, Ricardo Aguilar, Guillermo León Basantes, Patricia Casais, Cecilia C. Colorio, María Cecilia Guillermo Esposito, Pedro P. García Lázaro, Luis A. Meillon-García, Jaime Pereira, Suely Meireles Rezende, Juan Carlos Serrano, Mario L. Tejerina Valle, Felipe Vera, Lorena Karzulovic, Gabriel Rada, Holger Schünemann

Blood Adv (2021) 5 (15): 3032–3046.

https://doi.org/10.1182/bloodadvances.2021004267

Published: 2021

Includes: Supplemental data

Journal Articles

Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry

Jean-Pierre Bassand, Saverio Virdone, Marc Badoz, Freek W. A. Verheugt, A. John Camm, Frank Cools, Keith A. A. Fox, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gloria Kayani, Frank Misselwitz, Karen S. Pieper, Alexander G. G. Turpie, Martin van Eickels, Ajay K. Kakkar

Blood Adv (2021) 5 (4): 1081–1091.

https://doi.org/10.1182/bloodadvances.2020003560

Published: 2021

Includes: Supplemental data

Journal Articles

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khorana, Andrew D. Leavitt, Agnes Y. Y. Lee, Fergus Macbeth, Rebecca L. Morgan, Simon Noble, Elizabeth A. Sexton, David Stenehjem, Wojtek Wiercioch, Lara A. Kahale, Pablo Alonso-Coello

Blood Adv (2021) 5 (4): 927–974.

https://doi.org/10.1182/bloodadvances.2020003442

Published: 2021

Includes: Supplemental data

Journal Articles

Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism

Olivia S. Costa, Christine G. Kohn, Nicole M. Kuderer, Gary H. Lyman, Thomas J. Bunz, Craig I. Coleman

Blood Adv (2020) 4 (17): 4045–4051.

https://doi.org/10.1182/bloodadvances.2020002242

Published: 2020

Journal Articles

An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms

Annette von Drygalski, Vikas Bhat, Andrew J. Gale, Patricia M. Averell, Thomas J. Cramer, Darlene J. Elias, John H. Griffin, Laurent O. Mosnier

Blood Adv (2020) 4 (15): 3716–3727.

https://doi.org/10.1182/bloodadvances.2020001699

Published: 2020

Includes: Supplemental data

Journal Articles

Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure

Joseph R. Shaw, Na Li, Thomas Vanassche, Michiel Coppens, Alex C. Spyropoulos, Summer Syed, Mansoor Radwi, Joanne Duncan, Sam Schulman, James D. Douketis

Blood Adv (2020) 4 (15): 3520–3527.

https://doi.org/10.1182/bloodadvances.2020002335

Published: 2020

Includes: Supplemental data

Journal Articles

DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines

Ignacio Neumann, Ariel Izcovich, Yuqing Zhang, Gabriel Rada, Susan R. Kahn, Frederick Spencer, Suely Rezende, Franchesco Dentali, Kenneth Bauer, Gian Paolo Morgano, Juan J. Yepes-Nuñez, Robby Nieuwlaat, Wojtek Wiercioch, Liming Lu, Jiaming Wu, Mary Cushman, Holger Schunemann

Blood Adv (2020) 4 (7): 1512–1517.

https://doi.org/10.1182/bloodadvances.2019000840

Published: 2020

Includes: Supplemental data

Journal Articles

The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis

Leonard Naymagon, Douglas Tremblay, Nicole Zubizarreta, Erin Moshier, Kevin Troy, Thomas Schiano, John Mascarenhas

Blood Adv (2020) 4 (4): 655–666.

https://doi.org/10.1182/bloodadvances.2019001310

Published: 2020

Journal Articles

Managing patients who are receiving warfarin or a direct oral anticoagulant and need an elective surgery or procedure

James Douketis, Andrea Cervi

Blood Adv (2019) 3 (12): 1925.

https://doi.org/10.1182/bloodadvances.2019000171

Published: 2019

Includes: Supplemental data

Journal Articles

A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation

Miney Paquette, Daniel M. Witt, Anne Holbrook, Jane Skov, Jack Ansell, Holger J. Schünemann, Wojtek Wiercioch, Robby Nieuwlaat

Blood Adv (2019) 3 (10): 1638–1646.

https://doi.org/10.1182/bloodadvances.2019000067

Published: 2019

Includes: Supplemental data

Journal Articles

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors

Manu T. Kalathottukaren, A. Louise Creagh, Srinivas Abbina, Genmin Lu, Mark J. Karbarz, Anjali Pandey, Pamela B. Conley, Jayachandran N. Kizhakkedathu, Charles Haynes

Blood Adv (2018) 2 (16): 2104–2114.

https://doi.org/10.1182/bloodadvances.2016003616

Published: 2018

Includes: Supplemental data

Journal Articles

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, Alvaro Alonso

Blood Adv (2018) 2 (3): 200–209.

https://doi.org/10.1182/bloodadvances.2017010694

Published: 2018

Includes: Supplemental data

Journal Articles

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants

Jordan K. Schaefer, Suman L. Sood, Brian Haymart, Xiaokui Gu, Xiaowen Kong, Eva Kline-Rogers, Steven Almany, Jay Kozlowski, Gregory D. Krol, Scott Kaatz, James B. Froehlich, Geoffrey D. Barnes

Blood Adv (2017) 1 (26): 2536–2540.

https://doi.org/10.1182/bloodadvances.2017012377

Published: 2017

Journal Articles

The direct oral anticoagulants: can we finally stop using rat poison?

Mark Crowther

Blood Adv (2017) 1 (14): 980.

https://doi.org/10.1182/bloodadvances.2017002907

Published: 2017

Includes: Supplemental data

NARROW

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America

Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism

An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms

Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure

DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines

The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis

Managing patients who are receiving warfarin or a direct oral anticoagulant and need an elective surgery or procedure

A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants

The direct oral anticoagulants: can we finally stop using rat poison?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only